Carbotero 150 mg contains Carboplatin, a platinum-based chemotherapy agent widely used to treat various solid tumours.
Administered as an intravenous infusion, carboplatin is known for its effectiveness combined with a somewhat more favourable side effect profile than its older cousin, cisplatin.
It plays a major role in the management of ovarian, lung, and several other cancers, helping to shrink tumours, slow progression, and improve survival.

Mechanism of Action

Carboplatin works by directly damaging the DNA inside cancer cells:

• It forms platinum-DNA adducts, causing cross-linking of DNA strands.

• This prevents the DNA from properly uncoiling and replicating, ultimately stopping cancer cells from dividing and triggering programmed cell death (apoptosis).

Because cancer cells divide more rapidly than normal cells, they are more vulnerable to this kind of DNA disruption.

Uses / Indications

Carbotero (carboplatin) is used for the treatment of:

• Ovarian cancer, as first-line therapy or for recurrent disease, often combined with paclitaxel.

• Non-small cell and small cell lung cancer, frequently part of multi-drug regimens.

• Head and neck cancers, bladder cancer, esophageal cancer, and others, depending on oncologist protocols.

• Sometimes used off-label in other solid tumours or as a radiosensitiser (to enhance radiotherapy).

  Adverse Effects

  Carboplatin, like most chemotherapies, can affect normal rapidly dividing cells in addition to cancer cells.

  Common side effects include:

  • Bone marrow suppression, leading to low white cells (increased infection risk), low platelets (bleeding risk), and anaemia. This is often the dose-limiting toxicity, meaning it’s the main factor deciding how much drug can be safely given.

  • Mild nausea and vomiting, generally less intense than with cisplatin and well-controlled with modern antiemetics.

  • Fatigue, taste changes.